AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.
|Articles|October 2, 2015
7-year-old with bald spot, what’s your diagnosis?
A 7-year-old girl is brought into the office for evaluation of eczema. On review of symptoms, her mother mentions concern about a bald spot above the daughter's right ear, noticeable when she braids her hair.
Advertisement
A 7-year-old girl is brought into the office for evaluation of eczema. On review of symptoms, her mother mentions concern about a bald spot above the daughter's right ear, noticeable when she braids her hair.
Advertisement
Related to this article
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Day 1 of EADV 2026 brought new data across atopic dermatitis, cutaneous lupus, skin cancer, AI, climate-related skin disease, and more.
Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.
Advertisement
Advertisement
Trending on Dermatology Times
1
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
2
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
3
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
4
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
5